Literature DB >> 24267973

Long-term results for trigeminal schwannomas treated with gamma knife surgery.

Toshinori Hasegawa1, Takenori Kato, Hiroshi Iizuka, Yoshihisa Kida.   

Abstract

PURPOSE: Surgical resection is considered the desirable curative treatment for trigeminal schwannomas. However, complete resection without any complications remains challenging. During the last several decades, stereotactic radiosurgery (SRS) has emerged as a minimally invasive treatment modality. Information regarding long-term outcomes of SRS for patients harboring trigeminal schwannomas is limited because of the rarity of this tumor. The aim of this study was to evaluate long-term tumor control and functional outcomes in patients harboring trigeminal schwannomas treated with SRS, specifically with gamma knife surgery (GKS). METHODS AND MATERIALS: Fifty-three patients harboring trigeminal schwannomas treated with GKS were evaluated. Of these, 2 patients (4%) had partial irradiation of the tumor, and 34 patients (64%) underwent GKS as the initial treatment. The median tumor volume was 6.0 cm(3). The median maximum and marginal doses were 28 Gy and 14 Gy, respectively.
RESULTS: The median follow-up period was 98 months. On the last follow-up image, 7 patients (13%) had tumor enlargement, including the 2 patients who had partial treatment. Excluding the 2 patients who had partial treatment, the actuarial 5- and 10-year progression-free survival (PFS) rates were 90% and 82%, respectively. Patients with tumors compressing the brainstem with deviation of the fourth ventricle had significantly lower PFS rates. If those patients with tumors compressing the brainstem with deviation of the fourth ventricle are excluded, the actuarial 5- and 10-year PFS rates increased to 95% and 90%, respectively. Ten percent of patients had worsened facial numbness or pain in spite of no tumor progression, indicating adverse radiation effect.
CONCLUSIONS: GKS can be an acceptable alternative to surgical resection in patients with trigeminal schwannomas. However, large tumors that compress the brainstem with deviation of the fourth ventricle should be surgically removed first and then treated with GKS when necessary.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24267973     DOI: 10.1016/j.ijrobp.2013.09.010

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Clinical and Imaging Response to Trigeminal Schwannoma Radiosurgery: A Retrospective Analysis of a 28-Year Experience.

Authors:  Ajay Niranjan; Sudesh S Raju; Hideyuki Kano; John C Flickinger; Lawrence Dade Lunsford
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-14

2.  Stereotactic radiosurgery for non-vestibular cranial nerve schwanommas.

Authors:  Myreille D'Astous; Allen L Ho; Arjun Pendharkar; Clara Y H Choi; Scott G Soltys; Iris C Gibbs; Armine T Tayag; Patricia A Thompson; John R Adler; Steven D Chang
Journal:  J Neurooncol       Date:  2016-10-17       Impact factor: 4.130

3.  Neuroanatomical Determinants of Secondary Trigeminal Neuralgia: Application of 7T Ultra-High-Field Multimodal Magnetic Resonance Imaging.

Authors:  Annie E Arrighi-Allisan; Bradley N Delman; John W Rutland; Amy Yao; Judy Alper; Kuang-Han Huang; Priti Balchandani; Raj K Shrivastava
Journal:  World Neurosurg       Date:  2019-11-29       Impact factor: 2.104

4.  Gamma knife radiosurgery for trigeminal schwannoma: a 20-year experience with long-term treatment outcome.

Authors:  Jiwook Ryu; Sung Ho Lee; Seok Keun Choi; Young Jin Lim
Journal:  J Neurooncol       Date:  2018-06-21       Impact factor: 4.130

Review 5.  Tumor control and trigeminal dysfunction improvement after stereotactic radiosurgery for trigeminal schwannomas: a systematic review and meta-analysis.

Authors:  Iulia Peciu-Florianu; Jean Régis; Marc Levivier; Michaela Dedeciusova; Nicolas Reyns; Constantin Tuleasca
Journal:  Neurosurg Rev       Date:  2020-11-13       Impact factor: 3.042

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.